M. Mavridis

Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease

M. Mavridis, A.‐D. Degryse, A. Lategan et al. · Neuroscience · 1991 · 213 citations

Life Sciences, Neurology, Neuroscience +17

S 16924 ((R)-2-{1-[2-(2,3-Dihydro-Benzo[1,4] Dioxin-5-Yloxy)-Ethyl]-Pyrrolidin-3yl}-1-(4-Fluoro-Phenyl)-Ethanone), a Novel, Potential Antipsychotic with Marked Serotonin (5-HT)1A Agonist Properties: II. Functional Profile in Comparison to Clozapine and Haloperidol

Mark J. Millan, Rudy Schreiber, Anne Dekeyne et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 87 citations

Medicine, Neuroscience, Pharmacology +17

Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats byα1 as compared toα2 agonists and antagonists

M. Mavridis, Françis C. Colpaert, Mark J. Millan · Brain Research · 1991 · 61 citations

Medicine, Neuroscience, Pharmacology +16

Dopamine–opiate interaction in the regulation of neostriatal and pallidal neuronal activity as assessed by opioid precursor peptides and glutamate decarboxylase messenger RNA expression

M. Mavridis, Marie‐Jo Besson · Neuroscience · 1999 · 22 citations

Life Sciences, Neurobiology, Neuroscience +8